SCHEMBL19734873

SCHEMBL19734873

BC(Br)(C(N)=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.54
KMT2A Q03164 1/20 0.54
KCNN4 O15554 11/20 0.47
HTT P42858 1/20 0.44
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
POLB P06746 1/20 0.41
CYP3A4 P08684 1/20 0.41
PARP1 P09874 1/20 0.41
TSHR P16473 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KCNE1 P15382 1/20 0.40
KCNQ1 P51787 1/20 0.40
CYP2D6 P10635 2/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19734736 0.79 MAPT (0.56) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL25968774 0.76 MAPT (0.58) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL20629141 0.76 MAPT (0.63) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL14040482 0.76 CES1 (0.50) MAPTKMT2ACYP1A2CYP2C19POLB
SCHEMBL830791 0.73 MAPT (0.60) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL812971 0.73 KCNN4 (0.76) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL27702859 0.73 MAPT (0.59) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL11602590 0.73 MAPT (0.65) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL366365 0.71 MAPT (0.58) MAPTKMT2AKCNN4HTTCYP1A2
SCHEMBL10811339 0.71 MAPT (0.58) MAPTKMT2AKCNN4HTTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 US disclosed
WO-2017216726-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed
WO-2017216727-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 DNMT1, DNMT3A, DNMT3B MAPT 3289/4885KMT2A 121/4885KCNN4 2233/4885
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 DNMT1, DNMT3A, DNMT3B MAPT 3289/4885KMT2A 121/4885KCNN4 2233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.